Drug discovery and manufacturing is rapidly changing across the pharmaceutical industry. The increased focus on rare diseases, along with breakthroughs in biologics, gene and cell therapy, and other forms of personalized medicine, have empowered bold innovation among drug developers. Many companies are leveraging these scientific advancements to pursue a new aspirational focus on finding cures for the most-difficult-to-treat diseases. As ...

Boom in cell and gene therapy Among these segments is cell and gene therapy, where innovative science in areas such as cardiovascular disease, cancer, and genetic disorders is driving rapid R&D activity to address critical unmet patient needs. Recent scientific successes in cell and gene therapy are fostering robust venture investment in start-ups, as well as a flurry of mergers ...

Robust capital investment is driving extraordinary growth in the life sciences industry. According to Pitchbook, a researcher covering the venture and private equity markets, $2.8 billion has already been invested in pharma and biotech startups in the first quarter of 2018. This investment level is on track to eclipse the record $10 billion that was invested in 2017. New companies ...